Clarient
Total Raised
$65.65MInvestors Count
29Deal Terms
3Funding, Valuation & Revenue
15 Fundings
Clarient has raised $65.65M over 15 rounds.
Clarient's latest funding round was a Acquired for on October 21, 2015.
Clarient's valuation in October 2010 was $587M.
Clarient's latest post-money valuation is from October 2015.
Sign up for a free demo to see Clarient's valuations in October 2015 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/21/2015 | Acquired | 1 | ||||
10/25/2010 | Acq - P2P | $587M | 1 | |||
5/5/2009 | PIPE - III | $40M | ||||
9/7/2006 | PIPE - II | |||||
12/7/2005 | PIPE |
Date | 10/21/2015 | 10/25/2010 | 5/5/2009 | 9/7/2006 | 12/7/2005 |
|---|---|---|---|---|---|
Round | Acquired | Acq - P2P | PIPE - III | PIPE - II | PIPE |
Amount | $40M | ||||
Investors | |||||
Valuation | $587M | ||||
Revenue | |||||
Sources | 1 | 1 |
Clarient Deal Terms
3 Deal Terms
Clarient's deal structure is available for 3 funding rounds, including their Acquired from October 21, 2015.
Round | Acquired | Acq - P2P | Series B |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired | |||||||||||||||
Acq - P2P | |||||||||||||||
Series B |
Clarient Investors
29 Investors
Clarient has 29 investors. NeoGenomics Laboratories invested in Clarient's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/21/2015 | 10/21/2015 | 1 Acquired | Corporation | Florida | ||
10/25/2010 | 10/25/2010 | 1 Acq - P2P | Corporation | Illinois | ||
5/5/2009 | 5/5/2009 | 1 PIPE - III | Venture Capital | Connecticut | ||
Private Equity | Pennsylvania | |||||
Asset/Investment Management | New York |
First funding | 10/21/2015 | 10/25/2010 | 5/5/2009 | ||
|---|---|---|---|---|---|
Last Funding | 10/21/2015 | 10/25/2010 | 5/5/2009 | ||
Investor | |||||
Rounds | 1 Acquired | 1 Acq - P2P | 1 PIPE - III | ||
Board Seats | |||||
Type | Corporation | Corporation | Venture Capital | Private Equity | Asset/Investment Management |
Location | Florida | Illinois | Connecticut | Pennsylvania | New York |
Compare Clarient to Competitors
Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.
PointCare Technologies is a medical diagnostics company focused on point of treatment diagnosis. Its main product, PointCare NOW, is a flow cytometry system that provides hematology testing and CD4 lymphocyte counting, which aids in the management of HIV/AIDS patients by delivering blood analysis results in one process. The company serves the healthcare sector with technologies that support the diagnosis and treatment of HIV/AIDS. It was founded in 2002 and is based in Marlborough, Massachusetts.
Brain Tunnelgenix Technologies focuses on brain temperature monitoring through non-invasive healthcare technology. The company provides services for tracking human brain temperature using their proprietary Brain Thermal Tunnel, applicable in various sectors such as healthcare, sports, military, and home use. It was founded in 2006 and is based in Aventura, Florida.
Founded in 1998, Investigen, Inc., is an innovator in DNA testing, developing new processes to shorten testing time and reduce the cost of DNA diagnostic testing and detection of microorganisms and genetically modified organisms (GMOs). Investigen's tests have already demonstrated significant value for food quality assurance, health care, environmental safety, and industry.http://www.investigen.comDidier Perez, Phone: 510-964-9700, Email: didier@investigen.com
Minomic is a cancer diagnostics company specializing in tests for solid tumors, with a focus on prostate cancer. The company offers MiCheck® Prostate, a blood test that assesses the risk of clinically significant prostate cancer to aid in biopsy decisions. Minomic primarily serves the healthcare sector. It was founded in 2007 and is based in Macquarie Park, New South Wales.
Ligon Discovery focuses on the commercialization of small molecule microarray (SMM) technology within the pharmaceutical and diagnostic sectors. The company's main offerings include applications of SMM technology to facilitate discovery processes in pharmaceutical and diagnostic industries. It is based in Cambridge, Massachusetts.
Loading...